cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28945290
title: Assessment of physicians’ perception of pediatrics respiratory syncytial virus disease and preferences for immunization strategies in the United States

description: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants and young children, placing substantial burden on patients, their families, and health systems. This observational, cross-sectional, web-based, survey study in the United States (during October – November 2023) assessed physicians’ perceptions of RSV disease and new immunization strategies, including their preferences for monoclonal antibodies (mAbs) and maternal immunizations as RSV preventive measures. Immunization preferences were quantified through discrete choice experiment (DCE). Physicians aged ≥ 18 years, who spent at least 60% of their time in direct patient care and worked in a practice providing immunization to patients aged ≤ 2 years were recruited through online panels. Eighty pediatricians and 20 family practitioners participated. Mean (SD) age of physicians was 52.3 (12.7) years; majority were male (64.0%). Most physicians strongly agreed with supporting all types of recommended childhood immunizations (77.0%) and were aware of new RSV immunization strategies under development or recently approved (91.0%). A majority moderately/strongly agreed that maternal immunization and mAbs provide protection to the baby (77.0% and 87.0%, respectively). In DCE, physicians chose RSV immunization 96.1% of the time vs no immunization (3.9%). The most important attributes that drove physicians’ preferences were: increasing durability of protection from 90 to 180 days (24.9%), increasing efficacy against RSV hospitalization from 57% to 80% (20.9%), and increasing efficacy against medically-attended RSV from 51% to 80% (20.2%). Understanding physicians’ attitudes and preferences regarding RSV immunization strategies is important as new RSV prevention methods become available and are introduced into clinical practice.
DOI: 10.6084/m9.figshare.28945290.v1
title: Assessment of physicians’ perception of pediatrics respiratory syncytial virus disease and preferences for immunization strategies in the United States

description: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants and young children, placing substantial burden on patients, their families, and health systems. This observational, cross-sectional, web-based, survey study in the United States (during October – November 2023) assessed physicians’ perceptions of RSV disease and new immunization strategies, including their preferences for monoclonal antibodies (mAbs) and maternal immunizations as RSV preventive measures. Immunization preferences were quantified through discrete choice experiment (DCE). Physicians aged ≥ 18 years, who spent at least 60% of their time in direct patient care and worked in a practice providing immunization to patients aged ≤ 2 years were recruited through online panels. Eighty pediatricians and 20 family practitioners participated. Mean (SD) age of physicians was 52.3 (12.7) years; majority were male (64.0%). Most physicians strongly agreed with supporting all types of recommended childhood immunizations (77.0%) and were aware of new RSV immunization strategies under development or recently approved (91.0%). A majority moderately/strongly agreed that maternal immunization and mAbs provide protection to the baby (77.0% and 87.0%, respectively). In DCE, physicians chose RSV immunization 96.1% of the time vs no immunization (3.9%). The most important attributes that drove physicians’ preferences were: increasing durability of protection from 90 to 180 days (24.9%), increasing efficacy against RSV hospitalization from 57% to 80% (20.9%), and increasing efficacy against medically-attended RSV from 51% to 80% (20.2%). Understanding physicians’ attitudes and preferences regarding RSV immunization strategies is important as new RSV prevention methods become available and are introduced into clinical practice.
DOI: 10.6084/m9.figshare.30092390
title: Identification of multifunctional T-cell peptide epitopes for the development of DNA vaccines against dengue virus

description: Dengue virus (DENV) is an important arthropod-borne virus that poses a global health threat, with half of the world’s population at risk of infection. Currently, there is a lack of safe and effective vaccines for its prevention. Antibody-dependent enhancement (ADE) occurs when cross-reactive antibodies fail to neutralize heterologous DENV serotypes effectively, facilitating viral entry into Fc receptor-bearing cells and leading to more severe disease. It is reported that multifunctional T cells are closely related to the protective effects of the vaccine. We selected 25 peptide candidates based on predictions from the IEDB database and relevant literature. These peptides were validated to stimulate the production of multifunctional T cells. The DNA sequences of the corresponding peptides were cloned into the pVAX1 vector, and monovalent DNA vaccines for DENV 1–4 were constructed. <i>We analyzed cellular immunity, symptom scores, body weight changes, and survival rates after DENV challenge with the identical immunizing strain</i>.Our studies confirmed that DNA vaccines can protect mice against DENV challenge. Compared with control groups, mice immunized with our DNA vaccines demonstrated better immune protection after being challenged with the corresponding strain of DENV. Our studies provide a basis for the development of new DENV tetravalent vaccines. In this study, we developed novel DNA vaccines targeting dengue fever, a disease caused by four distinct serotypes of the dengue virus (DENV1–4). Our vaccines are designed to include key T-cell epitopes from each serotype, enhancing the immune system’s ability to recognize and respond effectively. The results from our experiments showed that our vaccines induce strong multifunctional T-cell responses in test animals, providing robust immunity against all four serotypes. Furthermore, the vaccines demonstrated safety and efficacy in animal trials, paving the way for future human trials. This innovative approach promises comprehensive and lasting immunity against dengue, addressing the limitations of current vaccines and significantly impacting global health efforts. Our work underscores the importance of developing broad-spectrum vaccines to tackle diseases with multiple serotypes, making it relevant for both scientists and non-scientists alike.
DOI: 10.6084/m9.figshare.30092390.v1
title: Identification of multifunctional T-cell peptide epitopes for the development of DNA vaccines against dengue virus

description: Dengue virus (DENV) is an important arthropod-borne virus that poses a global health threat, with half of the world’s population at risk of infection. Currently, there is a lack of safe and effective vaccines for its prevention. Antibody-dependent enhancement (ADE) occurs when cross-reactive antibodies fail to neutralize heterologous DENV serotypes effectively, facilitating viral entry into Fc receptor-bearing cells and leading to more severe disease. It is reported that multifunctional T cells are closely related to the protective effects of the vaccine. We selected 25 peptide candidates based on predictions from the IEDB database and relevant literature. These peptides were validated to stimulate the production of multifunctional T cells. The DNA sequences of the corresponding peptides were cloned into the pVAX1 vector, and monovalent DNA vaccines for DENV 1–4 were constructed. <i>We analyzed cellular immunity, symptom scores, body weight changes, and survival rates after DENV challenge with the identical immunizing strain</i>.Our studies confirmed that DNA vaccines can protect mice against DENV challenge. Compared with control groups, mice immunized with our DNA vaccines demonstrated better immune protection after being challenged with the corresponding strain of DENV. Our studies provide a basis for the development of new DENV tetravalent vaccines. In this study, we developed novel DNA vaccines targeting dengue fever, a disease caused by four distinct serotypes of the dengue virus (DENV1–4). Our vaccines are designed to include key T-cell epitopes from each serotype, enhancing the immune system’s ability to recognize and respond effectively. The results from our experiments showed that our vaccines induce strong multifunctional T-cell responses in test animals, providing robust immunity against all four serotypes. Furthermore, the vaccines demonstrated safety and efficacy in animal trials, paving the way for future human trials. This innovative approach promises comprehensive and lasting immunity against dengue, addressing the limitations of current vaccines and significantly impacting global health efforts. Our work underscores the importance of developing broad-spectrum vaccines to tackle diseases with multiple serotypes, making it relevant for both scientists and non-scientists alike.
DOI: 10.6084/m9.figshare.29062725
title: Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals

description: Despite over 13 billion SARS-CoV-2 vaccine doses administered globally, persistent post-vaccination symptoms, termed post-COVID-19 vaccine syndrome (PCVS), resemble post-acute sequelae of COVID-19 (PASC). Symptoms like cardiac, vascular, and neurological issues often emerge shortly after vaccination and persist for months to years, mirroring PASC. We previously showed the S1 subunit of the SARS-CoV-2 spike protein persists in CD16+ monocytes after infection, potentially driving PASC. Approved vaccines (Pfizer, Moderna, Janssen, AstraZeneca) deliver synthetic S1 to elicit immunity, suggesting a shared mechanism. We hypothesized that vaccine-derived S1 persistence in CD16+ monocytes sustains inflammation akin to PASC, contributing to PCVS. We studied 50 individuals with PCVS symptoms lasting over 30 days post-vaccination and 26 asymptomatic controls, using (1) machine learning-based immune profiling to compare cytokine signatures with PASC, (2) flow cytometry to detect S1 in CD16+ monocytes, and (3) LC-MS to confirm S1 across vaccine types. We correlated S1 persistence with symptom duration and inflammation. Prior infection was excluded via clinical history, anti-nucleocapsid antibody tests, and T-detect assays, though definitive tests are lacking. Preliminary findings suggest S1 persistence in CD16+ monocytes and an associated inflammatory profile may contribute to PCVS. Further studies are needed to confirm causality and prevalence. SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-COVID-19 Vaccine Syndrome (PCVS).
DOI: 10.6084/m9.figshare.29062725.v1
title: Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals

description: Despite over 13 billion SARS-CoV-2 vaccine doses administered globally, persistent post-vaccination symptoms, termed post-COVID-19 vaccine syndrome (PCVS), resemble post-acute sequelae of COVID-19 (PASC). Symptoms like cardiac, vascular, and neurological issues often emerge shortly after vaccination and persist for months to years, mirroring PASC. We previously showed the S1 subunit of the SARS-CoV-2 spike protein persists in CD16+ monocytes after infection, potentially driving PASC. Approved vaccines (Pfizer, Moderna, Janssen, AstraZeneca) deliver synthetic S1 to elicit immunity, suggesting a shared mechanism. We hypothesized that vaccine-derived S1 persistence in CD16+ monocytes sustains inflammation akin to PASC, contributing to PCVS. We studied 50 individuals with PCVS symptoms lasting over 30 days post-vaccination and 26 asymptomatic controls, using (1) machine learning-based immune profiling to compare cytokine signatures with PASC, (2) flow cytometry to detect S1 in CD16+ monocytes, and (3) LC-MS to confirm S1 across vaccine types. We correlated S1 persistence with symptom duration and inflammation. Prior infection was excluded via clinical history, anti-nucleocapsid antibody tests, and T-detect assays, though definitive tests are lacking. Preliminary findings suggest S1 persistence in CD16+ monocytes and an associated inflammatory profile may contribute to PCVS. Further studies are needed to confirm causality and prevalence. SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-COVID-19 Vaccine Syndrome (PCVS).
DOI: 10.15468/dl.t6geu9
title: Occurrence Download

description: A dataset containing 33 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Guadeloupe",
 "TaxonKey is Photinus discoideus"
 ]
}

 The dataset includes 33 records from 14 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032014-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30155738
title: Documented vaccination as proof of immunity compared to serology in medical students

description: We analyzed immunity to vaccine-preventable diseases and the predictive value of documented vaccination <i>versus</i> serological results for medical students in Catalonia (Spain). Epidemiological study of antibody seroprevalence and vaccination in medical students at four teaching units of medicine. Blood samples were drawn from participants who completed an epidemiology questionnaire. For seven diseases, we calculated the positive predictive value (PPV) percentages (and 95% CI) reflecting the protection afforded by self-reported vaccination histories compared to serology results. We enrolled 146 medical students (participation 25.7%; 146/569), 79.5% (116/146) women, mean (SD) age 22.6 (1.6) years. Most students (84.2%; 123/146) were fully vaccinated, 18 were unaware of their vaccination status, and 5 students were not vaccinated. Of the six overseas students, only three could document their vaccination status (OR = 6.0; 95% CI: 1.1–31.8). In documented vaccination terms, PPVs for immunological protection were high for varicella (100%), COVID-19 (99.1%), hepatitis A (98.9%), and rubella (94.8%), but was substantially lower for measles (90.0%), mumps (85.9%), and hepatitis B (67.2%). The predictive value of documented vaccination history compared to serology as proof of immunity was above 90% for most vaccines except for measles, mumps, and hepatitis B. Documented vaccination as immunity evidence was studied for seven vaccine-preventable diseases.Positive predictive values were just 90.0% for measles, 85.9% for mumps, and 67.2% for hepatitis B.To administer booster doses as necessary, documented vaccination for measles, mumps, and hepatitis B should be contrasted with serology results. Documented vaccination as immunity evidence was studied for seven vaccine-preventable diseases. Positive predictive values were just 90.0% for measles, 85.9% for mumps, and 67.2% for hepatitis B. To administer booster doses as necessary, documented vaccination for measles, mumps, and hepatitis B should be contrasted with serology results.
DOI: 10.6084/m9.figshare.30155738.v1
title: Documented vaccination as proof of immunity compared to serology in medical students

description: We analyzed immunity to vaccine-preventable diseases and the predictive value of documented vaccination <i>versus</i> serological results for medical students in Catalonia (Spain). Epidemiological study of antibody seroprevalence and vaccination in medical students at four teaching units of medicine. Blood samples were drawn from participants who completed an epidemiology questionnaire. For seven diseases, we calculated the positive predictive value (PPV) percentages (and 95% CI) reflecting the protection afforded by self-reported vaccination histories compared to serology results. We enrolled 146 medical students (participation 25.7%; 146/569), 79.5% (116/146) women, mean (SD) age 22.6 (1.6) years. Most students (84.2%; 123/146) were fully vaccinated, 18 were unaware of their vaccination status, and 5 students were not vaccinated. Of the six overseas students, only three could document their vaccination status (OR = 6.0; 95% CI: 1.1–31.8). In documented vaccination terms, PPVs for immunological protection were high for varicella (100%), COVID-19 (99.1%), hepatitis A (98.9%), and rubella (94.8%), but was substantially lower for measles (90.0%), mumps (85.9%), and hepatitis B (67.2%). The predictive value of documented vaccination history compared to serology as proof of immunity was above 90% for most vaccines except for measles, mumps, and hepatitis B. Documented vaccination as immunity evidence was studied for seven vaccine-preventable diseases.Positive predictive values were just 90.0% for measles, 85.9% for mumps, and 67.2% for hepatitis B.To administer booster doses as necessary, documented vaccination for measles, mumps, and hepatitis B should be contrasted with serology results. Documented vaccination as immunity evidence was studied for seven vaccine-preventable diseases. Positive predictive values were just 90.0% for measles, 85.9% for mumps, and 67.2% for hepatitis B. To administer booster doses as necessary, documented vaccination for measles, mumps, and hepatitis B should be contrasted with serology results.
DOI: 10.6084/m9.figshare.28468733
title: Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer

description: The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. The study sought to assess the cost-effectiveness of T-DXd in both the United States (US) and Chinese healthcare systems. Markov models were developed to evaluate the overall cost, incremental cost-effectiveness ratio (ICER), quality-adjusted life years (QALYs), and life years (LYs) of treatment with T-DXd compared with docetaxel, nivolumab, and pyrotinib for patients in the US and China. The level of willingness-to-pay (WTP) in the US and China is 150,000/QALYs and 32,517/QALYs, respectively. Sensitivity analyses were carried out to ensure the precision of the model. T-DXd yielded additional QALYs of 0.63 and 0.06 with an ICER of $338997.84 and $1437258.33 per QALY, respectively, in the US compared to the docetaxel and nivolumab regimens. And T-DXd yielded additional QALYs of 0.63, 0.06, and 0.13 with an ICER of $137959.45, $623805.93, and $515447.12 per QALY, respectively, in China compared to the docetaxel, nivolumab, and pyrotinib regimens. Sensitivity analysis showed that the cost of drugs is the most influential factor. T-DXd provides substantial therapeutic benefit for NSCLC patients with HER2 mutations who have had previous treatment but is not deemed cost-effective in either the US or China when compared to docetaxel, nivolumab, and pyrotinib. Price reduction is perhaps the main way to make T-DXd cost-effective.
DOI: 10.6084/m9.figshare.28468733.v1
title: Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer

description: The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. The study sought to assess the cost-effectiveness of T-DXd in both the United States (US) and Chinese healthcare systems. Markov models were developed to evaluate the overall cost, incremental cost-effectiveness ratio (ICER), quality-adjusted life years (QALYs), and life years (LYs) of treatment with T-DXd compared with docetaxel, nivolumab, and pyrotinib for patients in the US and China. The level of willingness-to-pay (WTP) in the US and China is 150,000/QALYs and 32,517/QALYs, respectively. Sensitivity analyses were carried out to ensure the precision of the model. T-DXd yielded additional QALYs of 0.63 and 0.06 with an ICER of $338997.84 and $1437258.33 per QALY, respectively, in the US compared to the docetaxel and nivolumab regimens. And T-DXd yielded additional QALYs of 0.63, 0.06, and 0.13 with an ICER of $137959.45, $623805.93, and $515447.12 per QALY, respectively, in China compared to the docetaxel, nivolumab, and pyrotinib regimens. Sensitivity analysis showed that the cost of drugs is the most influential factor. T-DXd provides substantial therapeutic benefit for NSCLC patients with HER2 mutations who have had previous treatment but is not deemed cost-effective in either the US or China when compared to docetaxel, nivolumab, and pyrotinib. Price reduction is perhaps the main way to make T-DXd cost-effective.
DOI: 10.6084/m9.figshare.28437181
title: Mpox vaccine acceptance and its predictors among people who have risky sexual practices: A systematic review and meta-analysis

description: Acceptance of available mpox vaccines among high-risk groups with risky sexual exposure varies by country, complicating efforts to draw conclusions and design effective intervention strategies. Seventeen studies were reviewed using the Joanna Briggs Institute (JBI) appraisal checklist from various databases. Funnel plot and I<sup>2</sup> test assessed publication bias and heterogeneity. DerSimonian and Laird random-effects model estimated the pooled mpox vaccine acceptance. Eggers and Beggs tests evaluated the small study effect, while subgroup and sensitivity analyses identified sources of heterogeneity. Globally, the pooled mpox vaccine acceptance rate among individuals with risky sexual practices was 75.22% (95% CI: 68.60, 81.84), indicating significant heterogeneity (I<sup>2</sup> = 99.83%, <i>p</i> &lt; .001). Significant predictors of higher acceptance included multiple sexual exposures and recent Sexually Transmitted Infections or Diseases (STI/STD) diagnoses. Despite higher acceptance rates among high-risk groups, many remain hesitant, posing challenges for outbreak control. Targeted campaigns and education on the importance of the mpox vaccine are essential. A PROSPERO registered systematic review and meta-analysis of literatures using PRISMA checklist on the global mpox vaccine acceptance and its predictors among people who have risky sexual practices. Vaccination is the key strategy, among multifaceted approaches, to ensure the safety of high-risk population groups, during outbreaks of international concern like mpox. However, vaccine acceptance among people who have risky sexual practices varies between nations. Therefore, making conclusions on their willingness to receive the mpox vaccine and designing intervention strategies is very difficult. The research team has used systematic collection and analysis of relevant findings reported by scholars globally to generate consolidated estimate of vaccine acceptance and identify influencing factors on which interventions are designed to increase vaccination coverage among people who have risky sexual practices. The total number of studies included in this review was 17, and all of them were conducted in countries where mpox cases are reported. Our analysis revealed that despite higher acceptance rates among people who have risky sexual practice, many remain hesitant, posing challenges for outbreak control. The current review identified and informed important focus areas of intervention including targeted vaccination campaigns and education on mpox vaccine.